Dr. Ryan M. Rich, MD
Ophthalmology (Ophthalmology Physician)
2770 N Union Blvd, Suite 140
Colorado Springs, CO 80909
Who else practices at this address →
El Paso County is a federal mental health shortage area. About shortage areas
- Medicare participating
At a glance
- Medical school
- Saint Louis University School of Medicine (2001)
- Years since graduation
- 25
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 875
Licensed in Colorado since 2008, according to the Colorado Department of Regulatory Agencies. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2001Medical school: Saint Louis University School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Ophthalmology Physician primary
CO license DR.0046281 (first issued 2008; active) -
Retina Specialist (Ophthalmology) Physician
CO license DR.0046281 (first issued 2008; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Retina Consultants of Southern Colorado P C (8 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 875
- Services billed
- 66,550
- Patients’ average age
- 78
| Service | Times | Patients |
|---|---|---|
| Injection, faricimab-svoa, 0.1 mg | 55,440 | 148 |
| Imaging of retina | 2,816 | 912 |
| Injection, ranibizumab, 0.1 mg | 2,073 | 85 |
| Injection of drug into eye | 1,916 | 381 |
| Established patient problem focused exam of visual system | 833 | 405 |
| Established patient complete exam of visual system | 802 | 635 |
| Injection, aflibercept, 1 mg | 750 | 85 |
| Compounded drug, not otherwise classified | 498 | 140 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 465 | 450 |
| New patient office or other outpatient visit, 45-59 minutes | 160 | 160 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisolone Acetate Other prescribers in Colorado Springs, CO | 156 |
| Ciprofloxacin Hcl Other prescribers in Colorado Springs, CO | 123 |
| Difluprednate | 17 |
| Timolol Maleate Other prescribers in Colorado Springs, CO | 14 |
| Dorzolamide-Timolol (dorzolamide hcl/timolol maleat) Other prescribers in Colorado Springs, CO | 13 |
| Ketorolac Tromethamine Other prescribers in Colorado Springs, CO | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 1 payments worth $29.68 in total to this clinician.
| Apellis Pharmaceuticals, Inc. | $29.68 |
|---|
| Food and Beverage | $29.68 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 4 companies. The companies reported $114,444 in research payments for these studies, mostly to the institutions running them.
- A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
Regeneron Pharmaceuticals, Inc. · Recruiting · NCT06541704 - A Phase 2, Double Masked, Placebo Controlled, Dose Range Finding Study of Danicopan (ALXN2040) in Patients with Geographic Atrophy (GA) Secondary to Age Related Macular Degeneration (AMD)
Alexion Pharmaceuticals, Inc. - A Phase 1 SAD MD in Diabetic Macular Edema
Genentech, Inc. - OPEN LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY OF FARICIMAB in PATIENTS WITH nAMD
Genentech, Inc. - Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degener…
AbbVie Inc. - Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)
AbbVie Inc. · Recruiting · NCT07007065
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.